|Programm||"Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"|
An Open Prospective Study for the Use of Rapamycin after High-Risk-Keratoplasty First Results of a Pilot Study
Birnbaum F.1, Reinhard T.2, Sokolowska J.1, Mayer K.1, Reis A.1, Oellerich M.3, Sundmacher R.1
Purpose: Until now CSA and MMF are the only available systemic immunosuppressants for patients undergoing high-risk-keratoplasty. Regarding side-effects and individual intolerances the clinical testing of alternative immunosuppressants is desirable. Rapamycin has shown its immunosuppressive potential in the rat keratoplasty model. After kidney-transplantations Rapamycin is part of several immunosuppressive protocols. Aim of this study was to prove the effectiveness and safety of Rapamycin after penetrating high-risk-keratoplasty.